Didn't find what you were looking for?

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights 24 May 2026 Press Release The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 23 April 2026 Events AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More 17 March 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 March 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 March 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 March 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 March 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 March 2026 Press Release डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 March 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 7 March 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 20 February 2026 Events Meeting with our International KOLs Our team meeting with oncology KOLs from the US and Europe. Read More 5 February 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 January 2026 Publications Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 November 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 November 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 November 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 November 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More 3 November 2025 Events ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Read More 20 October 2025 Patents Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More 17 October 2025 Publications Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More 17 October 2025 Events ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Read More 16 September 2025 Publications PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Read More 16 September 2025 Publications Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. Read More 3 June 2025 Publications PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Read More 3 June 2025 Publications Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Read More 3 June 2025 Publications Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Read More 3 June 2025 Publications Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Read More 3 June 2025 Publications Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Read More 9 May 2025 Publications Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Read More 9 May 2025 Events ISMRC 2025 | 7-9 May, 2025 Actorius at ISMRC 2025 Read More 14 March 2025 Publications Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More 25 November 2024 Publications ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Read More 25 November 2024 Publications ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. Read More 25 November 2024 Publications ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Read More 17 September 2024 Publications ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. Read More 15 July 2024 Publications Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Read More 29 June 2024 Publications Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Read More 4 June 2024 Publications ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Read More 3 June 2024 Publications ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Read More 3 June 2024 Publications ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Read More 3 June 2024 Publications ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Read More 3 June 2024 Publications ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Read More 10 April 2024 Publications AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Read More 10 April 2024 Publications AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Read More 4 April 2024 Publications Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Read More 11 February 2024 Press Release Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More 24 October 2023 Publications ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Read More 20 September 2023 Publications Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. Read More 20 July 2023 Publications Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Read More 6 June 2023 Publications ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Read More 6 June 2023 Publications ASCO 2023: Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next! Read More 19 April 2023 Publications AACR 2023: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies. Read More 11 April 2023 Publications Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. Read More 6 March 2023 Press Release Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More 28 February 2023 Expert Insights TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. Read More 13 February 2023 Patents Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More 15 January 2023 Publications AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Read More 9 August 20222 Expert Insights OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare Read More 28 August 2022 Expert Insights Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Read More 9 August 2022 Expert Insights OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Read More 9 August 2022 Expert Insights Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. Read More 9 August 2022 Press Release Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More 9 August 2022 Expert Insights Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Read More 1 July 2022 Publications Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Read More 7 June 2022 Publications ASCO 2022: CTCs as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers. Read More 7 June 2022 Publications ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. Read More 7 June 2022 Publications ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Read More 7 June 2022 Publications ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. Read More 7 June 2022 Publications ASCO 2022: Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types. Read More 27 April 2022 Publications Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Read More 18 February 2022 Publications Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Read More 9 October 2021 Publications ESMO 2021: Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs) Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools. Read More 8 June 2021 Publications ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Read More 22 April 2021 Patents Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More 18 December 2020 Publications Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Read More 10 October 2020 Publications Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Read More 11 August 2020 Expert Insights OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. Read More 15 July 2020 Publications ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Read More 23 April 2020 Press Release Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More 15 March 2020 Publications ASCO 2020: Correlation of CTCs with disease progression in Indian oral cancer patients. In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification. Read More 26 February 2020 Patents Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More 29 August 2019 Press Release Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper Read More 28 August 2019 Press Release Dr. Jayant Khandare – Interview Excerpts on DD Sahyadri Dr. Jayant Khandare shares insights on cancer diagnostics and liquid biopsy advancements in his edited interview on DD Sahyadri, aired by Doordarshan Sahyadri. Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Read More 4 June 2019 Publications ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Read More 22 March 2019 Press Release Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. Read More 11 February 2018 Publications Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Read More 17 January 2018 Publications Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Read More 17 January 2017 Publications Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Read More 17 April 2015 Publications Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. Read More 13 April 2015 Publications Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Read More First Prev 1 Page 1 Next Last

Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers Publications 17 March 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Abstract Background Urological cancers, including prostate, bladder, kidney, testicular, and penile cancers, often fail to show symptoms or show only nonspecific symptoms at early stages. This leads to delayed diagnosis, treatment decisions, and outcomes. Circulating tumor cells (CTCs) predict the outcome in metastatic prostate cancer (PC). Furthermore, in bladder cancer, CTC positivity is linked to muscle invasion, higher recurrence risk, and worse clinical outcomes. CTC PD-L1 expression could evade immune elimination. In spite of complete remission, a higher percentage of patients are known to recur in urothelial cancers. CTCs acting as minimal cellular residual disease (MCRD) are highly implicated, knowing their capacity to be dormant systemically with extravasation and invasion to distant organs. We analyzed the presence of CTCs with PD-L1 over-expression in urological cancers at baseline and follow-ups. Methods Retrospectively, a total of 359 urological cancer patients were evaluated for CTC positivity, including 307 at baseline and 52 follow-up samples. The cancer type distribution was prostate cancer (n = 139), bladder (n = 188), kidney (n = 10), testes (n = 2), penis (n = 8), urothelial (n = 12), etc. Ninety-five percent of the patients were male (n = 293) and 5% were female (n = 14), with most patients aged 61 to 80 years. CTCs expressing PD-L1, positive CTCs, and CTC clusters were analyzed using OncoDiscover® PD-L1 markers and a Zeiss fluorescence automated microscope. Demographics, cancer mean distribution, and CTC and cluster frequency were analyzed. Results Of the 359 patients, CTCs were detected in 68.2% (245/359) of patients, while PD-L1 over-expression on CTCs was present in 49.9% (179/359) of patients. However, CTC clusters were uncommon and occurred in 7.2% (26/359) of patients. Across cancer types (total CTCs = 436), prostate cancer accounted for higher CTCs with a mean CTC distribution of 2.18, while bladder was 0.74, urothelial 0.34, testes 0.18, kidney 0.74, and penis 0.38, respectively. CTC PD-L1 was highest in prostate cancer (46.1%) compared to other cancers, and CTC cluster prevalence was 1.8% in prostate cancer, urothelial (0.9%), and bladder (0.2%) cancers. In CTC-positive cases, 56.3% of patients had only one CTC, 27.8% showed two CTCs, and 8.2% had three. The mean across all patients was 0.6 for CTCs, 0.3 for CTC-PD-L1 positive, and 0.1 for clusters. Conclusions CTCs with PD-L1-positive overexpression were observed across urological cancers, being particularly higher in prostate cancer compared to bladder, kidney, and penis cancers. Many patients are known to recur in spite of complete remission, possibly due to the presence of aggressive CTCs in circulation that could evade the immune system. More studies assessing the presence of CTCs with PD-L1 expression are justified in urological cancers for minimal cellular residual disease and as prognostication. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Biofunctionalized capillary platform with 3D matrix for efficient CTC capture. Publications 17 January 2017 Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Circulating tumor cells (CTCs) in peripheral blood provide valuable genetic information for cancer diagnosis and overall disease monitoring. The analysis of “liquid biopsy” holds immense promise, as it may lead to new approaches for cancer treatment. This study reports an effective continuous-flow microchannel system for isolating CTCs using a transferrin-conjugated 3D matrix synthesized by crosslinking polyethylene glycol–Fe₃O₄ nanostructures. This design enables rapid and efficient capture of CTCs. The platform also allows the use of multiple microchannel units in series, which can enhance cell capture efficiency by increasing the frequency of cell–substrate contact. CTCs were captured with high efficiency even at low target cell concentrations, achieving approximately 90% capture efficiency at 25 cells per mL of blood. Furthermore, the study demonstrates that cell capture performance is influenced by topographic interactions between the nanostructure-based matrix and the cancer cells of interest. In addition, this work presents a proof of concept using a 3D microchannel system capable of simultaneously capturing and permanently eliminating CTCs from peripheral blood samples. The study also evaluates clinical samples from colon and breast cancer patients for the rapid isolation of CTCs. Conclusively, the platform demonstrates a strong capacity for cancer cell sorting, biological studies of CTCs, and investigation of cancer metastasis, potentially benefiting real-time liquid biopsy applications and early cancer prognosis. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 profiling across cancers supports monitoring, recurrence detection, and MRD. Publications 3 June 2025 Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Background India presents a diverse genetic pool with varying cancer incidence patterns. Common cancers in the Indian population include head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers. Understanding the distribution of circulating tumor cells (CTCs) across these cancers may help account for cellular minimal residual disease (MRD) and early recurrence in solid tumors. Surgery with curative intent can be further evaluated for residual disease using dual biomarkers such as ctDNA and CTCs. Methods In this retrospective analysis, peripheral blood samples from 5,935 patients across various cancer types—including head and neck, lung, breast, colorectal, prostate, ovarian, and gastrointestinal cancers—were evaluated for the presence of CTCs, with and without PD-L1 overexpression and CTC clusters. CTCs were detected using the OncoDiscover platform approved by CDSCO in 1.5 mL of peripheral blood. The platform utilizes a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibodies. CTCs were confirmed as EpCAM⁺, CK18⁺, DAPI⁺, and CD45⁻ cells. PD-L1 expression on CTCs was analyzed using linear fluorescence intensity gradients acquired through an automated Zeiss microscope. Additionally, a computational model was developed to evaluate CTC frequency, mean distribution, regression analysis, and normal probability plots to assess predictability across cancer types, age groups, stages, and genders. Results The study included 5,935 patient blood samples, comprising 90.07% baseline and 9.92% follow-up samples. CTC counts ranged from 1 to 10 per 1.5 mL of blood, with a mean value of 1.12. Among the patients, 69.87% (n = 2,854) demonstrated PD-L1 expression on their CTCs, with a mean value of 0.99. The 51–60-year age group exhibited the highest proportion of both total CTCs (19.16%, n = 1,137) and PD-L1–positive CTCs (19.71%, n = 805). Most CTC clusters were identified in breast, colorectal, and endometrial cancers. Pancreatic cancer patients showed the highest mean CTC count (1.4), whereas laryngeal cancer samples had the lowest mean count (0.78). The computational model indicated that the 51–60-year age group had the highest impact on cancer prevalence and mean CTC distribution. The model also demonstrated a strong correlation between blood-based outcomes and normal probability scores. Conclusions Higher CTC counts were strongly associated with advanced disease stages, particularly in cancers prone to hematogenous spread, such as breast, lung, and prostate cancers. Incorporating CTC profiling from baseline into diagnostic and surveillance strategies may enhance personalized cancer management. The presence of CTCs in disease-free survival (DFS) settings suggests potential links to poor therapeutic response, disease progression, and minimal residual disease. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magnetic nanocrystals capture tumour cells from blood samples Press Release 11 February 2024 Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Cellulose-based magnetic nanocrystals and nanofibres can capture circulating tumour cells (CTCs) from the blood samples of head and neck cancer patients. A magnet is used to separate the trapped tumour cells, which are then identified under a fluorescence microscope. This technique could potentially be used to monitor cancer progression in real time, says an international team, which included researchers at North Dakota State University, USA, the Tata Memorial Hospital in Mumbai, and Actorius Innovations and Research, and Dr. Vishwanath Karad MIT World Peace University, both in Pune. Click the below link to read the full article. Know More Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO Aravindan Vasudevan Cofounder & Director Rick Kamble Cofounder & Director Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Self-propelled CNT microrockets enable rapid capture and isolation of CTCs. Publications 13 April 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. We demonstrated a novel carbon nanotube (CNT)-based microrocket that propels efficiently through the thrust generated by oxygen (O₂) bubbles. These self-propelled microrockets exhibit ultrafast propulsion in aqueous solutions as well as in Dulbecco’s modified Eagle’s medium (DMEM). The microrocket generated a driving force of over 231 and 300 pN in DMEM containing 4% hydrogen peroxide (H₂O₂). The speed and distance traveled by the microrocket can be controlled by adjusting the concentration of H₂O₂. The designed multifunctional microrocket has the ability to (i) rapidly target (~5 minutes) and efficiently capture (~85%) transferrin receptor–positive (TfR⁺) cancer cells from an artificial CTC-like suspension, (ii) magnetically isolate the captured cells from peripheral blood cells, and (iii) enable subsequent high-resolution imaging. We envision that such self-powered micromotors could provide a novel and effective approach for the rapid and efficient extraction of circulating tumor cells (CTCs) from biological fluids, supporting early cancer diagnosis and detection of recurrence. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Automated OncoMetastat device enables CTC removal to support cancer therapy outcomes. Publications 3 November 2025 Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Introduction Despite no radiological evidence of minimal residual disease, up to 25–50% of colorectal cancer (CRC) stage II–III and breast cancer cases experience relapse. Identifying patients at risk of recurrence remains challenging, as approximately 90% of cancer-related deaths are associated with metastasis. The role of circulating tumor cells (CTCs) in extravasation and seeding of distant organs is well established; however, their extracorporeal isolation has not been widely demonstrated in routine practice. Current ex vivo CTC isolation systems often require complex setups and extensive manual handling. In this study, we present an automated device designed to capture and remove CTCs from whole blood using biocompatible cartridges mediated by antibody- and transferrin-conjugated glass bead substrates. Methods We developed the OncoMetastat touchscreen-based operational control device, integrating six roller peristaltic pumps and a cartridge containing 680 targeting 2 mm glass beads functionalized with anti-epithelial cell adhesion molecule (EpCAM) antibodies and transferrin protein. The device housing (365 × 200 × 30 mm) contains a bi-spiral channel (95 × 95 × 10 mm) with 680 beads and eight cross-section channels (3.50 × 3.55 mm). A 3D-printed spring-loaded quick-release mechanism ensures secure tube attachment and rapid cartridge exchange. Flow performance, hemolysis, protein adsorption, and leukocyte interaction were evaluated using blood samples from healthy individuals and cancer patients across multiple cancer types, including breast, CRC, lung, and head and neck cancers. Pyrogenicity was assessed in rabbits according to ISO 10993-11 guidelines. Results The device maintained stable blood circulation at 0.5 mL/min for 5–10 mL whole blood samples using a dual snap-fit holder with a 2° angled offset. The peristaltic pump ensured consistent flow without compromising sample integrity. The bead-filled spiral channel effectively retained CTCs, while the integrated design reduced manual handling and improved reproducibility. Low hemolysis (1%), along with reduced serum protein and leukocyte interactions, was observed in both healthy and cancer patient samples. Selective CTC capture was demonstrated in 24 clinical samples across cancer types. All materials passed pyrogenicity testing, with no temperature elevation observed in accordance with guidelines. Conclusions The OncoMetastat device successfully depleted CTCs from cancer patient whole blood without adversely affecting blood components. The automated system provides stable blood flow and demonstrates proof of performance for extracorporeal CTC removal, with potential to enhance cancer therapy outcomes. View Publication Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magnetic nanogels enable optimized capture of circulating tumor cells from blood. Publications 11 February 2018 Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Magnetic nanogels (MNGs) are designed with the necessary features to function as highly efficient trapping materials for the challenging task of selectively capturing circulating tumor cells (CTCs) from the bloodstream. A key factor in this process is the ability to discriminate CTCs from hematological cells, which can be optimized by finely tuning the polymers used to link the targeting moiety to the MNGs. Here, we describe the relationship between the capturing efficiency of CTCs with overexpressed transferrin receptors and the different strategies used in polymer linkers to decorate these MNGs with transferrin (Tf). Heterobifunctional polyethylene glycol (PEG) linkers with varying molecular weights were coupled to transferrin in different ratios. Optimal results, with over 80% CTC capture efficiency, were obtained when three PEG linkers with a length of eight ethylene glycol (EG) units were used. These findings highlight the crucial role of linker design in developing efficient CTC-sorting systems. View Manuscript Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC and PD-L1 detection reveals residual disease despite clear radiological scans. Publications 4 June 2024 ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Background Despite no evidence of disease by radiological imaging, up to 30% of breast cancer cases are known to relapse after treatment with curative intent. The presence of circulating tumor cells (CTCs) in stage I–II cancer patients signals the activation of extravasation and invasion processes leading to micro-metastasis and may result in poor outcomes. CTCs in blood circulation at any stage of cancer indicate detectable minimal cellular disease (MCD). Thus, the longitudinal investigation of patients with such biomarkers remains highly important for predicting recurrence, therapy escalation, and dose modifications. The expression of programmed death-ligand 1 (PD-L1) on CTCs is a dynamic biomarker, and these cells may escape elimination by the immune system, indicating progression toward a metastatic phenotype. Methods Retrospectively, a cohort of 20 cancer patients (including lung, colorectal, breast, stomach, etc.) who had recently undergone treatment were investigated for the presence of CTCs using the CDSCO-approved OncoDiscover platform. The platform contains multi-component systems conjugated with anti-EpCAM antibodies on magnetic nanoparticles. All patients clinically represented stable disease based on previous radiological findings. CTC enumeration was performed using CD45-, EpCAM+, and CK18+ markers, along with the evaluation of PD-L1 overexpression in 1.5 ml of peripheral blood using automated motorized Zeiss fluorescence microscopy. Results Despite no radiological evidence of disease and clinically stable status, 75% (n = 15) of the selected patients showed at least one CTC. Among them, 55% (n = 11) had one CTC, 5% (n = 1) had two CTCs, and 15% (n = 3) had three CTCs. In addition, 50% (n = 10) of patients demonstrated PD-L1 expression on CTCs, while one patient exhibited a CTC cluster. Conclusions Patients showed circulating residual disease (CRD) despite clinically stable disease, indicating possible progression from localized to secondary disease. Longitudinal monitoring of CTCs with PD-L1 expression may reveal real-time residual disease, progression, regression, and actual response to treatment. CRD monitoring can improve curative outcomes by potentially enhancing progression-free survival (PFS) and overall survival (OS) in solid cancers. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Magneto-polymeric nanosystems for rapid CTC targeting, detection & imaging. Patents 22 April 2021 Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Patent Details Related patent documents CA2976614 TH175113 WO/2016/132265 EP3259598 ES2828025 PL3259598 US20230408525 Granted Canadian, European and Indian Patent Actorius Innovations and Research Pvt. Ltd. View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Polymer-based drug delivery for targeted GI tract release (stomach, intestine, colon). Patents 26 February 2020 Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Patent Details Related patent documents CA3060026 EP3612196 WO/2018/193337 US20200129442 US20230181479 Granted US and Indian Patent Actorius Innovations and Research View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe